TLR4 and neoplasm: STING/TLR4 co-loaded lipid nanoparticles (immuno-NPs) enable systemic delivery, maintaining payload stability while reducing systemic toxicity, and demonstrate potent efficacy in murine breast cancer models with 50-60% reduction in tumor weight versus vehicle controls (79).